Replies to post #246988 on Biotech Values

[DewDiligence]

…AbbVie got rid of [Atrasentan]…

More or less; this is the 2020 PR announcing the ABBV-Chinook Atrasentan deal:

https://www.businesswire.com/news/home/20200110005075/en/Chinook-Therapeutics-Obtains-Worldwide-Rights-from-AbbVie-to-Atrasentan-with-Plans-to-Develop-for-the-Treatment-of-Kidney-Diseases

Under the terms of the license agreement, Chinook obtains worldwide rights to all fields of use for atrasentan and assumes full responsibility for advancing the program going forward. AbbVie will receive an undisclosed upfront cash payment, potential future milestones and royalties, and an equity stake in Chinook.

This PR wasn’t posted on the message board because Chinook hadn’t yet gone public via the reverse-merger with ADRO (#msg-158654033).

[Whalatane]

Cio / Dew Have either of you looked at OMER's Narsoplimab ( OMS721) for Iga Nephropathy
P3 9 mth data due Q3
Has FDA breakthrough therapy and Orphan designation
Re ARDX ..FDA going for 6 mth review vs 2 mth ...even tho drug is currently on the market as IBSRELA for IBS-C . I'm wondering if they want more data on hyperkalemia in these patients as I saw that noted that in their IBSRELA PDF
Appreciate any thought you two ( or others here ) have on OMER

Kiwi